Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BORTEZOMIB Cause Polyomavirus-associated nephropathy? 77 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 77 reports of Polyomavirus-associated nephropathy have been filed in association with BORTEZOMIB (bortezomib). This represents 0.2% of all adverse event reports for BORTEZOMIB.

77
Reports of Polyomavirus-associated nephropathy with BORTEZOMIB
0.2%
of all BORTEZOMIB reports
17
Deaths
34
Hospitalizations

How Dangerous Is Polyomavirus-associated nephropathy From BORTEZOMIB?

Of the 77 reports, 17 (22.1%) resulted in death, 34 (44.2%) required hospitalization, and 16 (20.8%) were considered life-threatening.

Is Polyomavirus-associated nephropathy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BORTEZOMIB. However, 77 reports have been filed with the FAERS database.

What Other Side Effects Does BORTEZOMIB Cause?

Plasma cell myeloma (6,683) Off label use (4,754) Neuropathy peripheral (4,067) Drug ineffective (2,730) Diarrhoea (2,244) Thrombocytopenia (2,082) Death (2,025) Pneumonia (2,020) Fatigue (1,757) Neutropenia (1,530)

What Other Drugs Cause Polyomavirus-associated nephropathy?

TACROLIMUS (1,477) MYCOPHENOLATE MOFETIL (1,112) PREDNISONE (666) METHYLPREDNISOLONE (416) PREDNISOLONE (402) BASILIXIMAB (298) EVEROLIMUS (247) CYCLOSPORINE (246) MYCOPHENOLIC ACID (238) RITUXIMAB (236)

Which BORTEZOMIB Alternatives Have Lower Polyomavirus-associated nephropathy Risk?

BORTEZOMIB vs BOSENTAN BORTEZOMIB vs BOSENTAN\BOSENTAN BORTEZOMIB vs BOSULIF BORTEZOMIB vs BOSUTINIB BORTEZOMIB vs BOTOX

Related Pages

BORTEZOMIB Full Profile All Polyomavirus-associated nephropathy Reports All Drugs Causing Polyomavirus-associated nephropathy BORTEZOMIB Demographics